Patents by Inventor Todd Brady

Todd Brady has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING SJÖGREN-LARSSEN SYNDROME
    Publication number: 20250228840
    Abstract: The present invention relates to methods of treatment using a quinoline compound, or a pharmaceutically acceptable salt thereof, for treatment of a disease, disorder, or condition such as Sjögren-Larsson syndrome (SLS).
    Type: Application
    Filed: March 29, 2023
    Publication date: July 17, 2025
    Inventors: Todd Brady, Adam Brockman, Stephen Gitu Machatha
  • TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT
    Publication number: 20250127733
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: October 2, 2024
    Publication date: April 24, 2025
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Deuterated compounds and uses thereof
    Patent number: 12240816
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: November 8, 2023
    Date of Patent: March 4, 2025
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan MacDonald
  • Toxic aldehyde related diseases and treatment
    Patent number: 12128013
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: August 22, 2023
    Date of Patent: October 29, 2024
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Pharmaceutical formulations and uses thereof
    Patent number: 12064516
    Abstract: The present invention relates to pharmaceutical compositions and unit dosage forms comprising a quinoline compound, or a pharmaceutically acceptable salt thereof, which are useful for treatment of a disease, disorder, or condition such as inflammatory diseases, respiratory diseases, organ diseases, viral infections, and sequelae and associated conditions such as acute respiratory distress syndrome.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: August 20, 2024
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Adam Brockman, Stephen Gitu Machatha
  • TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT
    Publication number: 20240189260
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: August 22, 2023
    Publication date: June 13, 2024
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • DEUTERATED COMPOUNDS AND USES THEREOF
    Publication number: 20240132451
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: November 8, 2023
    Publication date: April 25, 2024
    Inventors: Todd BRADY, Scott Young, William A. Kinney, Susan MACDONALD
  • Deuterated compounds and uses thereof
    Patent number: 11845722
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: September 2, 2022
    Date of Patent: December 19, 2023
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald
  • Toxic aldehyde related diseases and treatment
    Patent number: 11771664
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: March 7, 2022
    Date of Patent: October 3, 2023
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • DRY EYE DISEASE BIOMARKERS AND THEIR USE FOR TREATMENT
    Publication number: 20230228744
    Abstract: The present invention relates to use of biomarkers of dry eye disease, and use of the biomarkers for selection of subjects for treatment and treatment of dry eye disease.
    Type: Application
    Filed: June 4, 2021
    Publication date: July 20, 2023
    Inventors: Todd BRADY, Stephen Gitu MACHATHA, Adam BROCKMAN
  • Toxic aldehyde related diseases and treatment
    Patent number: 11701331
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: July 18, 2023
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • DEUTERATED COMPOUNDS AND USES THEREOF
    Publication number: 20230174491
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: September 2, 2022
    Publication date: June 8, 2023
    Inventors: Todd BRADY, Scott Young, William A. Kinney, Susan Macdonald
  • QUINOLINE COMPOUNDS FOR TREATING LUNG, LIVER, AND KIDNEY DISEASES, DISORDERS, OR CONDITIONS
    Publication number: 20230149383
    Abstract: The present invention relates to the use of a quinoline compound, or a pharmaceutically acceptable salt thereof, for treatment of a respiratory disease, disorder, or condition selected from chronic cough, pneumonia, and pulmonary sepsis, or an organ L disease, disorder, or condition selected from alcohol induced hepatitis, minimal change disease, and focal segmental glomerulosclerosis.
    Type: Application
    Filed: April 13, 2021
    Publication date: May 18, 2023
    Inventors: Todd BRADY, Adam BROCKMAN, Stephen Gitu MACHATHA
  • QUINOLINE COMPOUNDS FOR TREATING RESPIRATORY DISORDERS AND VIRAL INFECTIONS
    Publication number: 20230131929
    Abstract: The present invention relates to the use of a quinoline compound, or a pharmaceutically acceptable salt thereof, for treatment of ARDS, viral infections, and other diseases, disorders, and conditions such as those described herein.
    Type: Application
    Filed: March 24, 2021
    Publication date: April 27, 2023
    Inventors: Todd BRADY, Adam BROCKMAN, Stephen Gitu MACHATHA
  • ALDEHYDE CONJUGATES AND USES THEREOF
    Publication number: 20220354857
    Abstract: The present invention provides compounds and methods of use thereof for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: April 13, 2021
    Publication date: November 10, 2022
    Inventors: Todd Brady, Scott Young, William A. Kinney
  • Deuterated compounds and uses thereof
    Patent number: 11459300
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: October 4, 2022
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald
  • TREATMENT OF DRY EYE DISEASE
    Publication number: 20220211691
    Abstract: The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating dry eye disease.
    Type: Application
    Filed: March 15, 2022
    Publication date: July 7, 2022
    Inventors: Todd Brady, Stephen Gitu Machatha
  • TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT
    Publication number: 20220202745
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: March 7, 2022
    Publication date: June 30, 2022
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • COMBINATION TREATMENT OF OCULAR INFLAMMATORY DISORDERS AND DISEASES
    Publication number: 20220184057
    Abstract: The present disclosure provides a combination of a fused bicyclic amine compound and an anti-inflammatory agent for treating ocular inflammatory disorders and diseases. Further provided are pharmaceutical compositions of the compound and the anti-inflammatory agent.
    Type: Application
    Filed: September 23, 2021
    Publication date: June 16, 2022
    Inventors: Todd Brady, Scott Young
  • FORMULATIONS FOR TREATMENT OF DRY EYE DISEASE
    Publication number: 20220133629
    Abstract: The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating dry eye disease.
    Type: Application
    Filed: October 12, 2021
    Publication date: May 5, 2022
    Inventors: David CLARK, Todd BRADY, Susan MACDONALD, Stephen Gitu MACHATHA